VIRACTA THERAPEUTICS INC. - COMMON STOCK

0,1552

30-января-25 15:45:00

15 мин. задержка

Акции

+0,0014

+0,91%

Сегодняшний диапазон

0,1485 - 0,1600

ISIN

N/A

Источник

NASDAQ

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

26 дек 2024 15:30:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

13 ноя 2024 06:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

06 ноя 2024 15:30:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

14 авг 2024 06:05:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

14 авг 2024 06:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces New Employment Inducement Grants

17 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

14 май 2024 06:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

09 май 2024 15:05:01 Источник Nasdaq GlobeNewswire
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

07 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma

15 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

01 апр 2024 07:30:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

07 мар 2024 15:05:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial

29 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 фев 2024 15:05:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Provides Clinical Update and Outlook for 2024

04 янв 2024 07:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma

12 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

04 дек 2023 07:30:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

09 ноя 2023 07:30:00 Источник Nasdaq GlobeNewswire
Viracta Therapeutics to Present at Upcoming Investor Conferences

07 ноя 2023 15:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.